Significant news surrounds Alnylam Pharmaceuticals with various market reactions. Its aggressive 2026 Revenue Guidance alongside launching the ambitious Alnylam 2030 Strategy has garnered attention, however, reactions among investment managers were mixed, with RBC Capital and Wells Fargo reducing the company's stock price target to $465 and $376 respectively. Jennison Associates LLC and Massachusetts Financial Services Co. MA continue to maintain their strong positions in Alnylam, despite Baillie Gifford & Co. and Wealth Enhancement Group slashing their stakes.
Alnylam made a significant investment of $250 million in an enzymatic ligation platform to meet global demand for its RNAi therapeutics. They also saw a surge after strong Q3 performance and raised Revenue Guidance for 2025. The company expanded its manufacturing in Massachusetts and announced changes to its board of directors. Alnylam stock saw an increase following RNAi pipeline progress and a rise in its short interest, indicating potential upside.
Despite several insider selling actions, analysts from Goldman Sachs reiterated their buy rating on the company's stock. The firm is also found a place in the Alliance for Genomic Discovery and was endorsed by the UK's drug-cost watchdog for their heart disease drug. In conclusion, many developments are shaping the investment story of Alnylam.
Alnylam Pharmaceuticals News Analytics from Fri, 25 Jul 2025 07:00:00 GMT to Sat, 24 Jan 2026 12:53:31 GMT - Rating 6 - Innovation 8 - Information 8 - Rumor 7
